Drug Trial Radar · NCT06165341
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 1, 2024
Primary completion
Aug 26, 2028
Study completion Aug 26, 2028
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver. People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study. After their last clinic visits, participants will have two choices: 1. They can complete this study and return to the clinic 3 and 6 months later so the study doctors can check for side effects; OR 2. If they meet the rules, they can join another study (called extension or continuation study), in which they will receive fazirsiran every 3 months and will continue to have health checks.
Conditions
- Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran InjectionDrug
Fazirsiran will be injected subcutaneously.
PlaceboDrug
Fazirsiran matching placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of study drug administration up to end of study (EOS) (Week 124)
- Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function ParametersTime frame: From start of study drug administration up to EOS (Week 124)
- Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung DensitometryTime frame: Baseline up to Week 100
- Number of Participants With Clinically Significant Changes in Vital SignsTime frame: From start of study drug administration up to EOS (Week 124)
- Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) ParametersTime frame: From start of study drug administration up to EOS (Week 124)
- Number of Participants With Clinically Significant Changes in Clinical Laboratory ParametersTime frame: From start of study drug administration up to EOS (Week 124)
Locations
41 sites in 13 countries. Site status is shown where the registry gives one.
St Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Mayo Clinic - PPDS
Phoenix, Arizona · Recruiting
University of Arizona Thomas D. Boyer Liver Institute
Tucson, Arizona · Recruiting
University of California San Diego
La Jolla, California · Recruiting
UCLA Pulmonary and Critical Care
Los Angeles, California · Recruiting
University of California Benioff Children's Hospital
San Francisco, California · Recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado · Recruiting
Schiff Center for Liver Diseases/University of Miami
Miami, Florida · Recruiting
Indiana University School of Medicine-Indianapolis
Indianapolis, Indiana · Recruiting
University Of Iowa Hospitals And Clinics
Iowa City, Iowa · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
University of Michigan Hospital - 1500 E Medical Center Dr
Ann Arbor, Michigan · Recruiting
Henry Ford Health System
Novi, Michigan · Recruiting
Mayo Clinic PPDS
Rochester, Minnesota · Recruiting
NYU Langone Medical Center
New York, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Texas Liver Institute American Research Corporation
San Antonio, Texas · Recruiting
Bon Secours St. Mary's Hospital
Newport, Virginia · Recruiting
LKH-Universitätsklinikum Graz
Graz, Austria · Recruiting
KABEG - Klinikum Klagenfurt Am Wörthersee
Klagenfurt, Austria · Recruiting
UZ Antwerpen
Antwerp, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Inspiration Research Limited
Toronto, Ontario, Canada · Recruiting
Hôpital de La Croix Rousse
Lyon, France · Recruiting
Hopital PONTCHAILLOU CHU de Rennes
Rennes, France · Recruiting
Hôpital Paul Brousse
Val-de-Marne, France · Recruiting
Universitätsklinikum der RWTH Aachen
Aachen, Germany · Recruiting
Charité - Campus Virchow-Klinikum
Berlin, Germany · Recruiting
Hannover Medical School
Hanover, Germany · Recruiting
Universitätsklinikum Tübingen
Tübingen, Germany · Recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy · Recruiting
ID Clinic Arkadiusz Pisula
Mysłowice, Poland · Withdrawn
CCA Hospital Braga
Braga, Portugal · Recruiting
Hospital Dr. Nélio Mendonça
Funchal, Portugal · Recruiting
Centro Hospitalar de Universitário de Santo António E.P.E
Porto, Portugal · Recruiting
Hospital Universitario Virgen del Rocio - PPDS
Seville, Spain · Recruiting
Karolinska Universitetssjukhuset Huddinge
Huddinge, Sweden · Recruiting
Universitätsspital Bern
Bern, Switzerland · Recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.